ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study

Our plain-English summary of ASO Author Reflections: Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights from a Multi-center Study, by S. Yaşar (Annals of Surgical Oncology, 2024).

The study

• Author: S. Yaşar
• Journal: Annals of Surgical Oncology
• Published: 2024;31(9):6276-6277
• Cited by: 1 article, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

In plain English

This is a short 'Author Reflections' commentary by the author of a multi-center study of treatments and outcomes in malignant peritoneal mesothelioma, a cancer of the abdominal lining. It is not the full study and gives no patient numbers, methods or numerical results from that study. The author wrote that the study confirmed survival was significantly prolonged when good cytoreduction was achieved. Cytoreduction is surgery to remove the tumor. The author also wrote that cytotoxic chemotherapy remained the best option for patients who were not candidates for curative surgery, and that a high cytoreduction (CC) score after surgery may cause harmful effects. Age, ascites, performance status, tissue type, gender and asbestos exposure were also evaluated for their effect on prognosis. The commentary does not say what was found for any of these factors, including asbestos exposure. The survival figures of 34 to 92 months mentioned in the piece come from other studies, not this one. The author concluded that treatment decisions need a broad, multidisciplinary perspective. The author also concluded that new effective drugs are needed, especially around surgery and for disease that has spread.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: author commentary (ASO Author Reflections) on the author's own multi-center study; not the research article itself
• Who was studied: patients with malignant peritoneal mesothelioma in a multi-center study; number of patients, centers, location and time period not stated in this commentary
• Exposure: the study looked at treatments (cytoreductive surgery, HIPEC, systemic chemotherapy); asbestos exposure was one of several factors examined for prognosis, with no fiber type, dose or result given
• Main results:
  • according to the author, the study confirmed that survival was significantly prolonged when good cytoreduction was expected and achieved in patients chosen for surgery (no figures given)
  • the author wrote that the study showed cytotoxic chemotherapy is still the best option for patients who are not candidates for curative surgery (no figures given)
  • the author wrote that a high postoperative CC score may cause detrimental effects (no figures given)
• The authors' conclusion: The author concluded that a broad perspective and multidisciplinary approach is needed when making treatment decisions, and that new and effective agents are needed, especially for use around surgery and for metastatic disease.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer, Mesothelioma, Peritoneal mesothelioma.

Medical terms in this study, explained in our Lexicon: Peritoneal Mesothelioma.

Related studies

• Analysis of Treatment Strategies and Outcomes in Malignant Peritoneal Mesothelioma: Insights From a Multi-Center Study — S. Yaşar, F. Yılmaz, et al. (2024)
• ASO Author Reflections: Improving Outcomes in Diffuse Malignant Peritoneal Mesothelioma: Challenges and Opportunities — J.C. Leinwand, M.D. Kluger (2020)
• ASO Author Reflections: Expert Surgical Evaluation is Critical for Patients with Diffuse Malignant Peritoneal Mesothelioma: Lessons Learned from Assessing Outcomes of 2000 Patients — L. Bijelic, T. Cannon (2020)
• ASO Author Reflections: Long-Term Survival Is Feasible After Complete CRS/HIPEC for Biphasic Peritoneal Mesothelioma — K. Chouliaras, K.I. Votanopoulos (2018)
• ASO Author Reflections: Hormonal Status May Impact Outcomes in Peritoneal Mesothelioma After CRS/HIPEC — K.C. Cummins, S.M. Ruff (2026)
• ASO Author Reflections: Management of Malignant Peritoneal Mesothelioma — T.R. Cushman, V. Verma, et al. (2018)

Browse more research in Annals of Surgical Oncology, or return to medical research.